Figure 2. Administration of CSF1Ri results in concomitant loss of NK cells.

Administration of CSF1Ri starting 8 days before resection results in loss of NK, CD8⁺, and myeloid cells in the tumor (A) and blood (B) as measured by flow cytometry. Ly6C^hi and Ly6C^lo cells represent inflammatory and patrolling monocytes, respectively. Monocytes, CD45.2⁺CD11b⁺CSF1R⁺; NK cells, CD45.2⁺CD3^–NK1.1⁺; CD8⁺ T cells, CD45.2⁺CD3⁺CD8α⁺; neutrophils, CD45.2⁺CD11b⁺Ly6G⁺; B cells, CD45.2⁺CD19⁺; CD4⁺ T cells, CD45.2⁺CD3⁺CD4⁺. Analysis was performed after gating on live singlets. (C) Administration of CSF1Ri starting 8 days before resection results in selective loss of CSF1R⁺ cells from the CD11b⁺ population in the blood (left panels) and tumor (right panels). CSF1R expression was visualized using CSF1R-reporter mice (MacGreen). (A–C) Each symbol represents an individual mouse. (A) Ctrl and CSF1Ri, n = 11. (B and C) Ctrl and CSF1Ri, n = 7. Mean ± SD. **P < 0.01, ***P < 0.005 (2-tailed Student’s t test with Welch’s correction). A representative experiment of 2 is shown.